A Phase II Study of Albumin Bound-Paclitaxel (AbraxaneTM) for Treatment of Recurrent or Metastatic Head and Neck Cancer With the Addition of Cetuximab (Erbitux) (IMC-225) on Disease Progression
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Paclitaxel (Primary) ; Cetuximab
- Indications Head and neck cancer
- Focus Therapeutic Use
- 11 Jan 2018 Status changed from active, no longer recruiting to discontinued.
- 24 Mar 2009 Official Title amended as reported by ClinicalTrials.gov.
- 12 Dec 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.